An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

Plus: How AI propelled Nvidia up the list and other insights from this year's survey of corporate reputations.

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span ...

As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

Novo Nordisk’s NVO shares gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

With that as the backdrop, here's a closer look at three names that could be worth more than Berkshire Hathaway just five ...

Eli Lilly (NYSE: LLY) sells many products across treatment areas, from immunology to neuroscience. The company sells ...

The nature of the beast is yes, these drugs come off patent; the demand is there and someone could produce it more cheaply’, ...